Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 6/20 | 0.52 |
| ▸ | MERTK | Q12866 | 6/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.49 |
| ▸ | BMPR1B | O00238 | 4/20 | 0.48 |
| ▸ | BMPR1A | P36894 | 4/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.48 |
| ▸ | ACVRL1 | P37023 | 4/20 | 0.48 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18616309 | 0.89 | AXL (0.50) | AXLMERTKMAP4K4BMPR1BBMPR1A | |
| SCHEMBL18615708 | 0.88 | AXL (0.62) | AXLMERTKMAP4K4BMPR1BBMPR1A | |
| SCHEMBL18615349 | 0.76 | MERTK (0.61) | AXLMERTKBMPR1BBMPR1ATGFBR1 | |
| SCHEMBL18617140 | 0.74 | AXL (0.51) | AXLMERTKMAP4K4CHEK1PIK3CB | |
| SCHEMBL3461772 | 0.73 | PIK3CD (0.57) | MAP4K4ACVR1PIK3CB | |
| SCHEMBL8807848 | 0.73 | HRH3 (0.62) | MAP4K4PARP1POLBKCNH2MEN1 | |
| SCHEMBL30108253 | 0.72 | AXL (0.46) | AXLMERTKMAP4K4BMPR1BBMPR1A | |
| SCHEMBL14202576 | 0.71 | PRMT6 (0.57) | MAP4K4PARP1POLBKCNH2MEN1 | |
| SCHEMBL12651155 | 0.71 | HRH3 (0.60) | CHEK1MEN1KMT2A | |
| SCHEMBL19806887 | 0.71 | BMPR1B (0.72) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2023-01-05 | — | — | US | disclosed |
| EP-3344613-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2020-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | AXL 30/4885MERTK 1/4885MAP4K4 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.